DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Rifapentine

Rifapentine

  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T

    WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T

  • AMEG Categorisation of Antibiotics

    AMEG Categorisation of Antibiotics

  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use

    EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use

  • Customs Tariff - Schedule

    Customs Tariff - Schedule

  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

  • Antibiotic Classes

    Antibiotic Classes

  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies

    Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies

  • Treatment Shortening for (Drug-Susceptible) Pulmonary TB: Building

    Treatment Shortening for (Drug-Susceptible) Pulmonary TB: Building

  • Review on Antibiotic Resistance

    Review on Antibiotic Resistance

  • An Activist's Guide to Rifapentine for The

    An Activist's Guide to Rifapentine for The

  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018

    Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018

  • Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva

    Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva

  • Common Antibiotics

    Common Antibiotics

  • Acinetobacter Baumannii Antibiotic Resistance Mechanisms

    Acinetobacter Baumannii Antibiotic Resistance Mechanisms

  • Priftin (Rifapentine) Tablets (5.3) Initial U.S

    Priftin (Rifapentine) Tablets (5.3) Initial U.S

  • Bacterial Challenges and Evolving Antibacterial Drug Strategy B

    Bacterial Challenges and Evolving Antibacterial Drug Strategy B

  • Development of New Novel Bacterial Topoisomerase Inhibitors As Promising Antibiotics with a 5-Amino-1,3-Dioxane Linker Moiety DI

    Development of New Novel Bacterial Topoisomerase Inhibitors As Promising Antibiotics with a 5-Amino-1,3-Dioxane Linker Moiety DI

  • Design, Synthesis, and Evaluation of Small Molecules in the Discovery of Novel Antimicrobial Agents Kimberly D

    Design, Synthesis, and Evaluation of Small Molecules in the Discovery of Novel Antimicrobial Agents Kimberly D

Top View
  • Statistical Analysis Plan for Clinical Study Report Ac-061A301 / Ac
  • PRIFTIN® (Rifapentine) Tablets, for Oral Use ——————————————— CONTRAINDICATIONS ——————————————— Known Hypersensitivity to Any Rifamycin
  • Customs Tariff - Schedule
  • Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI)
  • Rifamycin O, an Alternative Anti-Mycobacterium Abscessus Agent
  • Latent Tuberculosis Infection Treatment Regimens
  • TRS958.Indd I 12.04.10 16:01 WHO Library Cataloguing-In-Publication Data
  • 12-Dose Regimen for Latent TB Infection
  • N-Nitrosamines and Tuberculosis Medicines Rifampicin and Rifapentine
  • Quality of Tuberculosis Care Click
  • E.Johnson Supplementary
  • Handbook of Anti-Tuberculosis Agents
  • Antituberculotics and Antileprotics ●Tuberulosis (Consumption; TBC) – WHO Report: 2.109 Infected in 2009 ●Leprosy (Hansen Disese, Hanseniasis) – Approx
  • Drug-Induced Hyperpigmentation: Review and Case Series
  • Rifapentine Is Not More Active Than Rifampin Against Chronic Tuberculosis in Guinea Pigs
  • Pharmaceutical Composition and Kit for Treating Bacterial Infections
  • Treating Latent TB Infection – an Update
  • Anti-Leprosy Drugs: Modes of Action and Mechanisms of Resistance in Mycobacterium Leprae


© 2024 Docslib.org    Feedback